Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection.
A cloned cDNA (1.65 kb) containing the complete glycoprotein gene of the Josiah strain of Lassa virus was inserted into the thymidine kinase (TK) gene of the New York Board of Health (WYETH) strain of vaccinia virus. The Lassa virus glycoprotein precursor, GPC, and the posttranslational cleavage products, G1 and G2, were shown by Western blot analysis to be properly expressed in cells infected with the recombinant virus. Northern blot hybridization of total cytoplasmic RNA extracted from recombinant virus infected cells demonstrated the presence of RNA transcripts of appropriate size considering the site of transcription initiation from the vaccinia P7.5 promoter, the size of the Lassa glycoprotein gene, and the presumed location of the transcription terminator in the vaccinia thymidine kinase gene. All guinea pigs vaccinated with the recombinant virus survived a lethal challenge infection with Lassa virus, whereas 80% of control animals died. The vaccinated guinea pigs did, however, develop transient, low-grade, fevers and detectable viremias following infection with Lassa virus, indicating that protection was not complete.
Auperin
D D
DD
Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA 30333.
Esposito
J J
JJ
Lange
J V
JV
Bauer
S P
SP
Knight
J
J
Sasso
D R
DR
McCormick
J B
JB
D000818:Animals; D001116:Arenaviridae / Q000235:genetics*; D006023:Glycoproteins / Q000235:genetics; D006168:Guinea Pigs; D007835:Lassa Fever / Q000517:prevention & control*; D007836:Lassa virus / Q000235:genetics* / Q000276:immunology; D008297:Male; D011995:Recombination, Genetic; D014158:Transcription, Genetic; D014616:Vaccinia virus / Q000235:genetics; D014764:Viral Proteins / Q000096:biosynthesis / Q000235:genetics*; D014765:Viral Vaccines / Q000494:pharmacology
D006023:Glycoproteins; D014764:Viral Proteins; D014765:Viral Vaccines